NasdaqGM:VERABiotechs
Vera Therapeutics (VERA) Is Up 12.5% After Atacicept BLA Filing and Positive Phase 3 Data
Vera Therapeutics recently announced the submission of a Biologics License Application (BLA) for atacicept to the FDA under the Accelerated Approval Program, supported by positive interim data from the OriginIN 3 trial and late-breaking Phase 3 results presented at ASN Kidney Week and published in The New England Journal of Medicine.
An important insight is that atacicept's data highlight both substantial proteinuria reduction and a favorable safety profile, reinforcing its potential as a...